Search - tctmd.com

Displaying 121 - 140 of 444

Sort: Relevancy | Date

News Conference News TCT 2015

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Yael L. Maxwell

October 14, 2015

Presentation TCT 2015

Optimal DAPT Duration After DES

Presenter: George D. Dangas, Paul A. Gurbel, Somjot S. Brar

October 13, 2015

Presentation TCT 2015

Acute DAPT Decisions: Agent Selection and Whether to Load

Presenter: George D. Dangas, Paul A. Gurbel

October 13, 2015

Presentation TCT 2015

I Dont Believe DAPT Should Be Discontinued at or Before 12 Months After Elective DES Implantation!

Presenter: Eric R. Bates, Spencer B. King III, Daniel I. Simon

October 13, 2015

News Conference News TCT 2015

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

October 13, 2015

Presentation TCT 2015

DAPT Duration Case 2: An Elderly Patient With CKD and Left Main Bifurcation Stenting Postdischarge Course

Presenter: John A. Bittl, Gary L. Schaer, Gennaro Giustino

October 12, 2015

Presentation TCT 2015

DAPT Duration Case 1: An Elderly Patient With CKD and Left Main Bifurcation Stenting In-Hospital Course

Presenter: John A. Bittl, Gary L. Schaer, Gennaro Giustino

October 12, 2015

Presentation TCT 2015

Is Dropping Aspirin the Magic Solution?

Presenter: John A. Bittl, Gary L. Schaer, Pascal Vranckx

October 12, 2015

Presentation TCT 2015

Risk vs Benefit: Can We Determine Which Patients Should Be Treated With Long-term DAPT?

Presenter: John A. Bittl, Gary L. Schaer, Matthew T. Roe

October 12, 2015

Presentation TCT 2015

Does PEGASUS Inform the Debate?

Presenter: John A. Bittl, Gary L. Schaer, Stephen D. Wiviott

October 12, 2015

Presentation TCT 2015

Debate: The Optimal Duration of DAPT After DES Is Less Than 12 Months for Most!

Presenter: John A. Bittl, Gary L. Schaer, Tullio Palmerini

October 12, 2015

Presentation TCT 2015

Debate: The Optimal Duration of DAPT After DES Is More Than 12 Months for Most!

Presenter: John A. Bittl, Gary L. Schaer, Laura Mauri

October 12, 2015

Presentation TCT 2015

HOT TOPIC 2: Balancing Safety and Efficacy Endpoints How Do Net Clinical Benefit and Quality of Life Fit Into the Equation? FOCUS on DAPT, PEGASUS, and MATRIX: Statistical Perspective

Presenter: Bernard J. Gersh, William S. Weintraub, Stuart J. Pocock

October 12, 2015

Presentation TCT 2015

HOT TOPIC 2: Balancing Safety and Efficacy Endpoints How Do Net Clinical Benefit and Quality of Life Fit Into the Equation? FOCUS on DAPT, PEGASUS, and MATRIX: Clinical/Trialist Perspective

Presenter: Bernard J. Gersh, William S. Weintraub, Gregg W. Stone

October 12, 2015

Presentation TCT 2015

DAPT: A Prospective, Double-blind, Placebo-controlled Randomized Trial of 1-year Versus 2.5 Years of Dual Anti-platelet Therapy (Everolimus-Eluting Stent-Treated Subset)

Presenter: Spencer B. King III, Jagat Narula, James B. Hermiller Jr

October 12, 2015

Presentation TCT 2015

DAPT Duration After DES: Does 1 Size Fit All? Focused Commentary

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, John A. Bittl

October 12, 2015

Presentation TCT 2015

DAPT Duration After DES: Does 1 Size Fit All?

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, John A. Bittl

October 12, 2015

News Industry News

Medtronic Drug-Filled Stent Shows Promising Initial Results Following First Implants

October 12, 2015

News Conference News TCT 2015

DAPT Study Subanalysis Focuses on EES Subgroup

October 12, 2015

News Conference News TCT 2015

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

October 12, 2015

Advertisement

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Optimal DAPT Duration After DES

Acute DAPT Decisions: Agent Selection and Whether to Load

I Dont Believe DAPT Should Be Discontinued at or Before 12 Months After Elective DES Implantation!

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

DAPT Duration Case 2: An Elderly Patient With CKD and Left Main Bifurcation Stenting Postdischarge Course

DAPT Duration Case 1: An Elderly Patient With CKD and Left Main Bifurcation Stenting In-Hospital Course

Is Dropping Aspirin the Magic Solution?

Risk vs Benefit: Can We Determine Which Patients Should Be Treated With Long-term DAPT?

Does PEGASUS Inform the Debate?

Debate: The Optimal Duration of DAPT After DES Is Less Than 12 Months for Most!

Debate: The Optimal Duration of DAPT After DES Is More Than 12 Months for Most!

HOT TOPIC 2: Balancing Safety and Efficacy Endpoints How Do Net Clinical Benefit and Quality of Life Fit Into the Equation? FOCUS on DAPT, PEGASUS, and MATRIX: Statistical Perspective

HOT TOPIC 2: Balancing Safety and Efficacy Endpoints How Do Net Clinical Benefit and Quality of Life Fit Into the Equation? FOCUS on DAPT, PEGASUS, and MATRIX: Clinical/Trialist Perspective

DAPT: A Prospective, Double-blind, Placebo-controlled Randomized Trial of 1-year Versus 2.5 Years of Dual Anti-platelet Therapy (Everolimus-Eluting Stent-Treated Subset)

DAPT Duration After DES: Does 1 Size Fit All? Focused Commentary

DAPT Duration After DES: Does 1 Size Fit All?

Medtronic Drug-Filled Stent Shows Promising Initial Results Following First Implants

DAPT Study Subanalysis Focuses on EES Subgroup

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content